Abstract
The impact of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma (RCC) is discussed herein with consideration of prolonged survival and quality of life. A nephrectomy can be indicated in a patient with good performance status and pulmonary metastases when adjuvant immunotherapy is an option. In contrast, in a patient with poor performance status and/or metastases including multiple organs, a nephrectomy is not indicated. To relieve symptoms, options other than nephrectomy should be considered.
| Original language | English |
|---|---|
| Pages (from-to) | 1732-1737 |
| Number of pages | 6 |
| Journal | Gan to kagaku ryoho. Cancer & chemotherapy |
| Volume | 29 |
| Issue number | 10 |
| Publication status | Published - 2002 Oct |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'What is the impact of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma?'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS